Twenty years of dopamine research: individual differences in the response of accumbal dopamine to environmental and pharmacological challenges.
Individual differences in the dopaminergic system of the nucleus accumbens of rats have extensively been reported. These individual differences have frequently been used to explain individual differences in response to environmental and pharmacological challenges. Remarkably, only little attention is paid to the factors that underlie these individual differences. This review gives an overview of the studies that have been performed in our institute during the last 20 years to investigate individual differences in accumbal dopamine release. Data are summarised demonstrating that individual differences in accumbal dopamine release are due to individual differences in: the functional reactivity of the noradrenergic system, the accumbal concentration of vesicular monoamine transporters and tyrosine hydroxylase as well as in the quantal size of the presynaptic pools of dopamine. Our data are embedded in the available literature to create a model that illustrates the putative hardware giving rise to the individual-specific release of accumbal dopamine. An important role is contributed to individual differences in the reactivity of the: hypothalamic-pituitary-adrenal axes, the reactivity of second messenger systems as well in the aminergic reactivity of the accumbens shell and core. The consequences of the individual-specific make-up and reactivity of the nucleus accumbens on the regulation of behaviour and the response to drugs of abuse will also be discussed. Apart from agents that interact with dopaminergic receptors, re-uptake or breakdown, noradrenergic agents as well as agents that interact with vesicular monoamine transporters or tyrosine hydroxylase are suggested to have therapeutic effects in subjects that are suffering from diseases in which the dopaminergic system is disturbed.
Verheij
Michel M M
MM
Department of Cognitive Neuroscience (CNS), Division of Psychoneuropharmacology (PNF), Radboud University Nijmegen Medical Centre, 6525 EZ, Nijmegen, The Netherlands. M.Verheij@cns.umcn.nl
Cools
Alexander R
AR
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000818:Animals; D001519:Behavior / Q000187:drug effects; D002395:Catecholamines / Q000096:biosynthesis / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D004298:Dopamine / Q000266:history* / Q000502:physiology*; D015259:Dopamine Agents / Q000494:pharmacology*; D004777:Environment; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007206:Individuality; D009638:Norepinephrine / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D011954:Receptors, Dopamine / Q000187:drug effects; D012110:Reserpine / Q000627:therapeutic use; D013028:Space Perception / Q000187:drug effects; D019805:alpha-Methyltyrosine / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D002395:Catecholamines; D000697:Central Nervous System Stimulants; D015259:Dopamine Agents; D004791:Enzyme Inhibitors; D011954:Receptors, Dopamine; D019805:alpha-Methyltyrosine; D012110:Reserpine; D004298:Dopamine; D009638:Norepinephrine